Continuous Infusion of Recombinant Factor VIIa in Hemophilic Patients with Inhibitors: Safety, Monitoring, and Cost Effectiveness

The continuous infusion of recombinant activated factor VII (rFVIIa) was first described in 1996. Because of the significant benefits in convenience and cost that can be achieved with this mode of administration compared with bolus doses, the method was quickly adopted, albeit with many local variations. Some of those have been less favorable, resulting in hemorrhagic complications. The potential pitfalls and experiences from a large number of …